Skip To Main Content
This platform is for Australian healthcare professionals only
Campus
Campus

EVENT TWO

2023 Interactive Clinical Tutorial Series

Remission or 'super responders' in severe asthma:
what to target and when to switch?

Recorded on: 24 August 2023

In this second ADVENT meeting, armed with a clearer understanding of remission or super responders, it's time to explore the ultimate objectives of severe asthma management.

In pursuit of the goal of optimal patient quality of life, is disease control sufficient, or should we dream bigger? With an expanding arsenal of biologics, should treatment goals be set higher? How can suitable candidates be identified for specific treatments, and when treatment be switched?

Watch the four videos below to be a part of a dynamic exchange of ideas as our expert panel addresses crucial questions that will inform your approach to severe asthma management.

Remission or super responder in rheumatology: what has 20 years of experience with biologics shown us?

Dr Tellus shares her 20 years of experience of treating rheumatology patients with biologic therapy

Case 1: Comorbidities that may affect response to biologics

A/Prof Lee discusses how cofactors & comorbidities impact management of a patient with severe asthma

Case 2: Improving but not a super responder: should we switch treatments?

Prof Hew shares his insights on indications for, and considerations around switching biologics

What to target and when to switch? Q&A Discussion

Prof Phil Bardin & expert panel discuss the management of patients in the era of advanced therapies

Watch the 2020–2022 ADVENT and ASPIRE series developed and endorsed by Australian and international experts

At ADVENTprogram.com you can:

  • Access medical education resources
  • Review the latest science for type 2 inflammatory diseases
  • Explore your specific interests – select materials by category or topic

Login to ADVENTprogram.com

Access to ADVENTprogram.com is restricted to healthcare professionals. Registration is required to view content.

DUPIXENT (dupilumab) PBS Information: Authority Required.

Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with: chronic severe atopic dermatitis: OR uncontrolled severe asthma.  This product is not listed on the PBS for: children 6 months to 11 years of age with severe atopic dermatitis; children 6-11 years of age with moderate to severe asthma; adults with uncontrolled chronic rhinosinusitis with nasal polyps; or adults with moderate-to-severe prurigo nodularis.

Please review the full Product Information before prescribing Dupixent (dupilumab). Please review full product Information before prescribing Dupixent (dupilumab). Full Product Information is available from Sanofi-aventis Australia pty ltd here or by contacting 1800 818 806.

â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems

MAT-AU-2302087 (v1.0)  |  SEPTEMBER 2023